Vision
No one should die of cancer
Addressing the hallmarks of cancer lethality with
first-in-class ND-ADCs
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality
Mission
Exploiting novel biology to gain revolutionary power over cancer
Our Science
Our novel and first-in-class Nuclear- Delivered Antibody-Drug Conjugates™ (ND-ADCs) target an intracellular transporter called TM4SF1. TM4SF1 is highly expressed in the tumor micro- environment and carries proteins – and our antibodies – from the cell surface to the nucleus.
TM4SF1 has high expression across all solid tumors with a correlation to mortality. Expression is in both tumor cells and tumor vascular endothelium. Selective delivery to these cells may result in high therapeutic margin with little delivery to health tissue.
Exploiting the biology of TM4SF1 and the nuclear delivery of payloads may unlock exceptional efficacy through novel and potent mechanisms of action:
- Antiangiogenesis (regression of angiogenic tumor vasculature)
- Tumor cell killing (especially invasive and metastic tumor cells)
- Immune activation
Angiex’s lead ND-ADC, AGX101, will soon be heading to the clinic, and a pipeline of additional ND-ADCs is in discovery-stage development.
Our Values
Driven by science
Curious with a purpose, truthful, committed to accuracy and reproducibility
Creative and courageous
Innovative, thoughtful, gritty, aiming high but rolling up our sleeves and tending to detail
Contributors without ego
Resourceful, flexible, self aware, generous to others, comfortable both as teacher and student
Respectful and inclusive
Team oriented, cooperative, communicative, and present for one another
For life, for all
Motivated to save lives, driven to bring good to patients, shareholders, and coworkers
Leadership team
Extensive oncology drug development and commercialization experience
Marty J Duvall
Chief Executive Officer
- Former CEO of Tocagen and Oncopeptides
- Chief Commercial Officer at ARIAD Pharmaceuticals
- Oncology Therapeutic Franchise Head at Merck
- Head of Commercial at MGI Pharma and Abraxis Bioscience
- Global Head of Taxotere Medical and Marketing, Aventis
Paul Jaminet
, PhD
Founder, President & COO
- Angiex founder. Raised $130M in capital in 3 companies
- Former co-founder & executive in software technology, digital media, finance, and health businesses
- PhD in Physics, University of California, Berkeley; Astrophysicist, Harvard-Smithsonian Center for Astrophysics
Jason Sager
, MD
Chief Medical Officer
- Chief Medical Officer, Angiex
- Former CMO, Ikena Oncology
- Founder & CEO, Sagely Health
- Former Senior Medical Director, Sanofi-Aventis, and Medical Director, Novartis
Shou-Ching Jaminet
, PHD
Founder, Scientific Adviser
- World’s leading expert in TM4SF1
- Former Director, MGTP Laboratory, BIDMC, and Member of Faculty, Harvard Medical School
Hal Dvorak
, MD
Founder, SAB Chair
- Discovered VEGF-A
- Mallinckrodt Distinguished Professor of Pathology emeritus, Harvard Medical School
Board of Directors
Iain Dukes
Angiex
Marty J Duvall
Paul Jaminet
Errik Anderson
Alloy Therapeutics
Jason Camm
Thiel Capital
Fabian Hansen
Presight Capital
